Initial Experience with the E-liac® Iliac Branch Device for the Endovascular Aortic Repair of Aorto-iliac Aneurysm
Occlusion of internal iliac arteries during endovascular treatment (EVAR) of abdominal aortic (AAA) and common iliac artery aneurysms might be associated with ischemic pelvic complications. This study evaluates technical and clinical success, safety and mid-term results of a novel iliac branch device (IBD) for revascularization of the internal iliac artery (IIA) during EVAR.
Materials and Methods
Retrospectively, we identified 21 men (mean age 73.3 ± 6.2 years) treated for aorto-iliac aneurysms by use of a novel IBD (E-liac®, Jotec Hechingen, Germany). We analyzed safety (30-day survival), technical (no type I and III endoleaks, “EL”), clinical (no ischemic complications) success, mid-term patency of this IBD, peri-procedural complications, occurrence of type II ELs, rate of re-interventions and additional treatment of the revascularized IIA for landing zone preparation.
Twenty-three IBDs were implanted. Aneurysms of the ipsilateral IIA were present in 6/23 IIAs (26.1%). Super-selective branch embolization was performed in these patients and the landing zone for the iliac sidebranch stent-graft was within the superior gluteal artery. Mean follow-up was 341 days (range 4–1103 days). Technical success and 30-day survival were 100%. Clinical success was 95.2%. Primary patency of the IBDs was 100% at 12 months. Peri-procedural complications occurred in 3/21 patients (14.3%), none of them related to the IBD. AAA-related type II ELs were found in 6 patients (28.6%), IBD-related ELs in 4/23 IBDs (17.4%) (two type Ib, two type II endoleaks). Overall re-intervention rate was 23.8%, IBD-related 8.7%.
Utilization of the E-liac® IBD is safe and effective for the treatment of aorto-iliac aneurysms.
KeywordsAbdominal aortic aneurysms (AAA) Aneurysms Arterial intervention Endovascular treatment Endovascular aneurysm repair/endovascular aortic repair (EVAR)
Compliance with Ethical Standards
Conflict of interest
Marcus Wiedner has received travel support by Jotec (Hechingen, Germany). Jan Peter Goltz serves as investigator in clinical trials which are fully or partly sponsored by Jotec GmbH (Hechingen, Germany) and has received travel support and lecture fees from Jotec. All other authors have no potential conflicts of interest to declare.
Local ethical committee approval was granted (File No. 17-202A).
Details of Prior Presentation
Pre-elementary data were presented as an oral presentation at “Deutscher Röntgenkongress 2017” in Leipzig, Germany.
- 10.Heckenkamp J, Brunkwall J, Luebke T, et al. Novel chimney-graft technique for preserving hypogastric flow in complex aortoiliac aneurysms. J Cardiovasc Surg (Torino). 2012;53(6):773–6.Google Scholar